Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 318

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 318
---
 be sufficient disclosure, and, after such general notice, it will not be necessary to give special notice relating to any particular transaction. Qualification The shareholding qualification for directors may be fixed by the Company in general meeting, and unless and until so fixed no qualification shall be required. DIAMIR MANAGEMENT Directors and Executive Officers The table below lists Diamir’s officers and directors.

| Name                |     | Age |     | Position                                    |
| Alidad Mireskandari |     |  57 |     | Chief Executive Officer                     |
| Kira S. Sheinerman  |     |  55 |     | Executive Director, Secretary and Treasurer |
| Gary Anthony        |     |  63 |     | Chief Financial Officer                     |

Alidad Mireskandari, Ph.D., MBA, Chief Executive Officer.Dr. Mireskandari joined DiamiR in July 2022, and has over 12 years of life sciences industry experience with a focus on molecular diagnostic test development and commercialization, including regulatory and reimbursement expertise. Dr. Mireskandari most recently served as Chief Development Officer of Interpace Biosciences from 2013 to 2022, and prior to that as President & CEO of JS Genetics from 2009 to 2013. From 2000 to 2009, Dr. Mireskandari was a hedge fund manager in charge of Life Sciences trading portfolios of Nomura Securities, BNP Paribas and Raeburn Advisors. Prior to this experience, he was a consultant with PRTM’s life sciences industry group from 1998 to 2000 and a research fellow at National Institutes of Health’s National Cancer Institute from 1990 to 1996. Dr. Mireskandari holds his Ph.D. in Generics from George Washington University and his MBA from the University of Michigan Ross School of Business. Kira S. Sheinerman, Ph.D., MBA, Treasurer and Secretary, Executive Director.Kira Sheinerman joined DiamiR in September 2009, and is DiamiR’s Co-Founder and Executive Director. Dr. Sheinerman was also Executive Chairman of DiamiR, LLC prior to and after the Share Exchange. Since November 2015, Dr. Sheinerman has served as a Managing Director, Healthcare Investment Banking at H.C. Wainwright & Co., LLC, where she works on financial and strategic transactions for growth life sciences companies. Previously, she was a